Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System

Azacitidine (AZA) is currently a drug of choice for most of high-risk MDS patients. However, only 40-50% of MDS patients achieve clinical improvement with AZA. There is a need for a predictive clinical decision support tool that can identify MDS patients with higher or lower likelihood of AZA response. Ideally, patients with no chance of response would be spared of life-threatening toxicities and expense; while patients with high chance for response would receive maximized treatment.

Blood Journal 2018 Myelodysplastic Syndrome